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Abstract
Study Design: Health utility analysis.
Objectives: To determine the health state utility (HSU) of 1- and 2-level anterior cervical discectomy and fusion (ACDF) and
cervical disc replacement (CDR).
Methods: Data from the Medtronic Prestige Cervical Disc investigational device exemption studies was used. Four groups
were defined: 1-level ACDF, 1-level CDR, 2-level ACDF, and 2-level CDR. The 36-item Short Form Health Survey (SF-36)
was collected at baseline, 12 months, 24 months, 36 months, and 60 months postoperatively and converted into utility
scores for each time point. A repeated-measures 1-way analysis of variance (ANOVA) was used to detect differences
among groups. Tukey’s method for multiple comparisons was used to determine which means within the groups were
statistically different (P < .05).
Results:We found a statistically significant difference in HSU among groups as determined by repeated-measures 1-way ANOVA
(P¼ .0008). Post hoc analysis indicated that 1-level ACDF had a statistically lower utility score compared with 1- and 2-level CDR
(P ¼ .04 and P ¼ .02, respectively). Similarly, 2-level ACDF had lower utility values compared with 2-level CDR (P ¼ .010). One-
level ACDF utility values were not different from 2-level ACDF values (P ¼ .55). Similarly, 1-level CDR and 2-level CDR did not
have different utility values (P ¼ .67).
Conclusions: Overall, CDR had higher health state utility scores for 1- and 2-level procedures at every time point. This study
indicates that CDR results in a higher postoperative health utility state than ACDF, and may therefore be an effective alternative
to ACDF for treating degenerative conditions of the cervical spine.
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Introduction
Cervical disc replacement (CDR) is an increasingly
accepted and utilized strategy for the treatment of sympto-
matic cervical degenerative disc disease (DDD). Although
anterior cervical discectomy and fusion (ACDF) is generally
considered the gold standard for the treatment of DDD,
CDR may provide superior outcomes in terms of arm and
neck pain, neurological outcomes, range of motion, and
decreased secondary surgical procedures.1-10 Furthermore,
increased range of motion may theoretically reduce the rate
of adjacent level disease.11,12
In a health care atmosphere where increasing awareness of
the costs of care may guide treatment practices it is important to
compare interventions in their efficient utilization of resources.
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The 36-Item Short Form Health Survey (SF-36) is a nonspeci-
fic Health-Related Quality of Life (HRQoL) assessment that
has been validated to measure morbidity and surgical outcomes
in common spinal disorders.13,14 This assessment can be trans-
lated into a measure of cost-effectiveness called the health state
utility (HSU) value. Applying the HSU in cost-effectiveness
analysis (CEA) provides a measure of the effectiveness of a
procedure in terms of the change it produces in a patient’s life.
Utility values can range from 0 to 1, with 0 representing death
and 1 representing perfect health. These health state utility
values are aggregated to generate quality-adjusted life years
(QALYs). Data from the SF-36 can be converted into HSU
scores, allowing direct comparison of the health status of
patients receiving different interventions.
While CEAs have previously been used to compare CDR
with ACDF in the treatment of DDD, few have incorporated
HSU into the model analysis.15-18 The ability to accurately
define the utility of an intervention is a critical component to
determining the overall value of that strategy. The purpose of
this study was to therefore determine the HSU of 1- and 2-level
ACDF and CDR at various postoperative time points. These
values will form the basis for future CEA models that attempt
to define treatment strategies involving ACDF and CDR.
Materials and Methods
We performed a secondary analysis of the prospectively col-
lected Short Form 36 (SF-36) data from the 1- and 2-level
Prestige LP CDR investigation device exemption (IDE) stud-
ies. We did not conduct a randomized control trial. We secon-
darily analyzed deidentified data from a Food and Drug
Administration (FDA) IDE prospective randomized control
trial, and therefore did not require institution review board
approval. In the 1-level study, 240 patients underwent ACDF
and 280 underwent CDR. The patients in the CDR group were
adults with symptomatic cervical DDD that required surgery at
a single-level between C3 and C7. All patients had radiculo-
pathy and/or myelopathy that did not respond to nonoperative
management. All patients had no previous surgical intervention
at the involved or adjacent levels. Additionally, all patients had
preoperative Neck Disability Index (NDI) scores 30, and
preoperative neck and arm pain questionnaires 20. All
patients in the control (ACDF) group were from a previously
conducted FDA IDE, and had identical inclusion and exclusion
criteria. Similarly, in the 2-level study, 229 patients underwent
ACDF and 223 underwent CDR. Overall, 4 potential operative
states were considered: 1-level ACDF, 1-level CDR, 2-level
ACDF, and 2-level CDR. Inclusion and exclusion criteria for
the 2-level patients in the CDR group were the same as those
for the 1-level study, only that they experienced symptoms at 2
contiguous levels.
As part of the study, the SF-36 data was collected at base-
line, 12 months, 24 months, 36 months, and 60 months post-
operatively. SF-36 data was converted into health state utilities
at each time point using the Short Form–6 Dimension (SF-6D)
algorithm, which is a preference-based index obtained from a
sample of the general population using the recognized valua-
tion technique of standard gamble.19 The standard gamble tech-
nique presents an individual with a choice between a particular
health state and a gamble that can either improve or worsen that
health state. The individual is then asked what probability of
improvement would make them indifferent to choosing
between the current health state and the gamble. The SF-6D
is composed of 6 multilevel dimensions describing a total of
18 000 unique health states. Based on preference weights
obtained from a sample of the population, the SF-6D algorithm
assigns a utility value to a particular health state or to a treat-
ment state. Using a noncommercially licensed application of
the SF-6D algorithm, the SF-36 data from the IDE studies was
converted to utility values at each of the time points. The
SF-6D has been validated in comparison with other health
state utility tools such as the EuroQol 5D, and has been used
in a number of cost-effectiveness studies.20-22
Statistical Analysis
All statistical analyses were performed with Prism Graphpad
V7 (La Jolla, CA, USA). The means and standard deviations of
HSU scores were calculated for each potential operative state.
The mean utility scores for each state were compared to detect
an overall difference among groups with the use of a repeated-
measures 1-way analysis of variance (ANOVA). Tukey’s
method for multiple comparisons was performed to assess for
individual differences between the means of the 4 groups.
Statistical significance was taken at P < .05.
Results
Table 1 summarizes the calculated health state utility values for
1- and 2-level ACDF and CDR for each of the time points.
There was a statistically significant difference between groups
as determined by 1-way ANOVA with repeated measures,
F(2, 9) ¼ 15.63, P ¼ .0008 (Figure 1). A Tukey’s post hoc
analysis indicated that 1-level ACDF had a statistically lower
utility score at all time points when compared with 1- and
2-level CDR (P ¼ .04 and P ¼ .02, respectively) (Table 2).
Similarly, two-level ACDF was shown to have a lower utility
value at all time points when compared with 2-level CDR (P ¼
.010). One-level ACDF and 2-level ACDF were not shown to











Baseline 0.54 0.55 0.53 0.55
12 0.68 0.73 0.69 0.72
24 0.69 0.72 0.71 0.73
36 0.69 0.73 0.72 0.74
60 0.70 0.72 0.70 0.74
Abbreviations: ACDF, anterior cervical discectomy and fusion; CDR, cervical
disc replacement.
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have different utility values from one another at any time
point (P ¼ .55). Similarly, 1-level CDR and 2-level CDR did
not differ in their utility values at any time point (P ¼ .67).
Discussion
ACDF and CDR are 2 effective and successful strategies for the
treatment of symptomatic degenerative disc disease. There
have been a number of FDA IDE randomized control studies
that have reported short- and medium-term results for both 1-
and 2-level ACDF and CDR.1-10 These IDE disc arthroplasty
studies have provided a wealth of patient-derived outcomes for
both CDR and ACDF, including SF-36, EuroQol 5D, and Neck
Disability Index (NDI). In order to perform a CEA, these
patient-derived outcomes require conversion to a HSU value.
The objective of our study was to be the first to directly define
the HSU of 1- and 2-level ACDF and CDR at 5 years.
The utility values in our model were derived from the SF-36
data from a FDA IDE trial comparing outcomes of CDR and
ACDF. SF-36 was the chosen metric as it is a validated means
of translating these scores into a quantitative health utility
value for use in CE modeling.14,19 Using this data, the baseline
health state for 1- and 2-level DDD was determined. The base-
line health state scores were similar to those previously pub-
lished, which reported a single level DDD HSU of 0.54.23 For
the single level cohort, there was a statistical difference
between CDR and ACDF at every time point. Similarly, in the
2-level cohort, the calculated HSUs were significantly different
at all time points in favor of CDR. The 1- and 2-level ACDF
and CDR groups all showed a significant improvement from
the baseline scores at all time points. Furthermore, the
improvement in HSU appeared to be maintained out to 5 years
in all the groups. This would suggest that ACDF and CDR both
show a similar durability in the improvement of HSU at an
intermediate time point, with a greater HSU in 1- and 2-level
CDR compared with 1- and 2-level ACDF.
A number of cost-effectiveness analyses have been carried
out for different CDR devices. Radcliff et al16 obtained QALYs
using 7-year follow-up data from the ProDisc-C IDE study and
conducted a Monte Carlo simulation to compare cost-
effectiveness of CDR compared with ACDF for single-level
procedures. The authors found that CDR on average per-
patient had a cost savings of $12 789 and QALY gains of
0.16 compared to ACDF. They also determined CDR to be
more cost-effective in 90.8% of the 10000 simulations. Several
other studies have also found CDR to be more cost-effective
than ACDF for single-level procedures.17,18 For 2-level proce-
dures, Ament et al15 found CDR to be associated with a greater
cost of $2139 per patient, but also observed QALY gains of
0.087 per patient compared with ACDF. This yielded an incre-
mental cost-effectiveness ratio of $24594, far lower than the
commonly used $50000 per QALY. The authors therefore sug-
gest that CDR is an extremely cost-effective alternative to
ACDF, and postulated this may be due to the faster recovery
and earlier improvement in health states after CDR.
Our results suggest the benefits of CDR over ACDF with
regard to HSU, and several studies have also demonstrated the
clinical benefits of CDR over ACDF. Burkus et al24 indepen-
dently analyzed 5-year follow-up data from the Prestige CDR
IDE study. Of the 271 patients who completed 5-year follow-
up, 144 were treated with the investigational device (CDR) and
127 were treated with ACDF for single level DDD.24 The
authors found that at both 36- and 60-month time points post-
operatively, the CDR cohort had a greater improvement in neck
disability index scores as compared to the ACDF cohort. Simi-
larly, neurologic success rates were 8%, 9.6%, and 6.1%
greater in the CDR group as compared with the ACDF group
at 24-, 36-, and 60-month follow-up, respectively (P ¼ .006,
P ¼ .004, and P ¼ .051, respectively). The ACDF group expe-
rienced a 1.9% revision rate and 3.4% rate of supplemental
fixation compared with a 0% revision rate and 0% supplemen-
tal fixation rate in the CDR group. The authors concluded that
the Prestige CDR provided superior range of motion and out-
comes than ACDF for single level procedures, and was non-
inferior for a number of other outcomes such as arm pain, neck
pain, adjacent segment ossification, dysphagia, implant
removal, and adjacent-level surgery. A number of other
studies echoed these results for different types of CDR
devices.3,6,7,10,25 While we cannot conclude from our study that
devices other than the one we investigated have superior HSU
scores over ACDF, the homogeneity of results from clinical
Figure 1. Results of the one-way repeated-measures analysis of
variance. ACDF, anterior cervical discectomy and fusion; CDR,
cervical disc replacement.
Table 2. Tukey’s Post Hoc Analysis Comparing Means for Each
Simulation.
Levels Mean Difference P
One-Level ACDF vs One-Level CDR 0.03 .04
One-Level ACDF vs Two-Level ACDF 0.01 .55
One-Level ACDF vs Two-Level CDR 0.036 .02
One-Level CDR vs Two-Level ACDF 0.02 .07
One-Level CDR vs Two-Level CDR 0.006 .67
Two-Level ACDF vs Two-Level CDR 0.026 .010
Abbreviations: ACDF, anterior cervical discectomy and fusion; CDR, cervical
disc replacement.
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studies investigating different CDR devices does suggest we
may extrapolate our results to other devices.
An important aspect of the 2 treatment modalities (CDR vs
ACDF) involves preservation of range of motion. Radiographic
and cadaveric studies have demonstrated that ACDF restricts
range of motion, which may have an effect on the biomecha-
nics at adjacent levels.26-28 While the debate remains as to
whether adjacent-level degeneration results from fusion or is
simply a progression of the natural history of DDD, it is impor-
tant to note that the CDR devices preserve substantial range of
motion postoperatively.11,12 Kim et al12 demonstrated that
range of motion of the functional spinal unit and overall range
of motion during the early postoperative period (<3 months)
was statistically smaller compared with preoperative range of
motion, but after 3 months returned to levels comparable to
preoperative. This maintenance of range of motion may be not
only a benefit in itself but also may reduce the biomechanical
strains placed on the cervical spine. Theoretically, this may in
turn reduce adjacent segment degeneration and need for
adjacent-level surgery, which is corroborated by some of the
clinical studies comparing adjacent-level surgery following
CDR and ACDF.2,4
We observed that at 5 years for both 1- and 2-level
procedures CDR provides superior health state utility. These
findings, complemented by the literature on outcomes and
cost-effectiveness of CDR compared to ACDF, suggest
CDR as an effective alternative to ACDF for treating 1- and
2-level DDD.
Limitations
There are several limitations worth noting in the present study.
This study represents the results of a single manufacturer’s
implant. The results presented here may not be applicable to
other CDR devices, though we remain confident that our results
could be extrapolated to other devices. Another potential lim-
itation of this study is the use of the SF-36 to calculate the HSU
of patients having undergone CDR or ACDF. While conversion
of the SF-36 to a SF-6D is an accepted means of obtaining a
HSU value, the SF-36 remains a general health instrument and
is not specific to the spine. A more spine-specific measure of
HRQoL would have provided a more accurate assessment of
the true postoperative state of the patients in the 2 cohorts.
Finally, we used data from a FDA IDE study, and therefore
the data we used is subject to the same limitations of the
original study.
Conclusions
The health utility values for 1- and 2-level ACDF and CDR
were calculated for the preoperative baseline state, and at the
12-, 24-, 36-, and 60-month postoperative state. Overall, CDR
was found to have a higher health utility state for 1- and 2-level
procedures at every time point. One- and 2-level ACDF proce-
dures did not differ in their health utility state at any time point.
Similarly, 1- and 2-level CDR demonstrated similar health
utility score at every time point. This study suggests that CDR
results in a higher postoperative health utility state than ACDF.
Future prospective randomized trials are needed to confirm the
results of this study that demonstrate CDR may be an effective
alternative to ACDF for managing degenerative conditions of
the cervical spine.
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